These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19773087)

  • 21. Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine.
    Airas L; Niemelä J; Yegutkin G; Jalkanen S
    Ann N Y Acad Sci; 2007 Sep; 1110():641-8. PubMed ID: 17911479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease-modifying drugs for multiple sclerosis: current and future aspects.
    Freedman MS
    Expert Opin Pharmacother; 2006 Oct; 7 Suppl 1():S1-9. PubMed ID: 17020427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunopathogenesis of multiple sclerosis.
    Agrawal SM; Yong VW
    Int Rev Neurobiol; 2007; 79():99-126. PubMed ID: 17531839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Activation of psoriasis in patients undergoing treatment with interferon-beta].
    Navne JE; Hedegaard U; Bygum A
    Ugeskr Laeger; 2005 Aug; 167(32):2903-4. PubMed ID: 16109199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.
    Vandenbark AA; Huan J; Agotsch M; La Tocha D; Goelz S; Offner H; Lanker S; Bourdette D
    J Neuroimmunol; 2009 Oct; 215(1-2):125-8. PubMed ID: 19758707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
    Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
    Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-interferon for multiple sclerosis.
    Rudick RA; Goelz SE
    Exp Cell Res; 2011 May; 317(9):1301-11. PubMed ID: 21396360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
    J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis.
    Mirandola SR; Hallal DE; Farias AS; Oliveira EC; Brandão CO; Ruocco HH; Damasceno BP; Santos LM
    Int Immunopharmacol; 2009 Jul; 9(7-8):824-30. PubMed ID: 19289181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Nursing service for MS patients].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16518890
    [No Abstract]   [Full Text] [Related]  

  • 36. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.
    Pulicken M; Koteish A; DeBusk K; Calabresi PA
    Neurology; 2006 Jun; 66(12):1954-5. PubMed ID: 16801674
    [No Abstract]   [Full Text] [Related]  

  • 39. IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.
    Severa M; Rizzo F; Giacomini E; Salvetti M; Coccia EM
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):229-39. PubMed ID: 25498525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
    Freedman MS; Forrestal FG
    Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.